Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
2014 ◽
Vol 29
(9)
◽
pp. 978-986
◽
2017 ◽
Vol 27
(5)
◽
pp. 526-537
◽
1993 ◽
Vol 13
(6)
◽
pp. 429???437
◽
2005 ◽
Vol 87
(2-3)
◽
pp. 161-167
◽